With the purchase from IBA Molecular of its UK FDG business Alliance Medical, one of Europe’s leading independent provider of medical imaging services, has secured the future production of Fluorodeoxyglucose (FDG)
Under the terms of the deal, Alliance will take on IBA Molecular’s FDG production facilities in the UK, with IBA gaining a licensing agreement to supply Alliance PET/CT centres in Italy, Germany and Spain. IBA Molecular will continue its other UK nuclear medicine manufacturing activities as well as its FDG business in the rest of Europe. The transfer of the business will not alter arrangements with existing customers.
The creation of an integrated Radiotracer supply and imaging organization now provides the only integrated molecular imaging service in the UK. FDG radiotracer has to be used within a few hours of manufacture. For this reason, manufacturing plants need to be close to where scanners are located, as it cannot be either imported or stockpiled.
The IBA Molecular deal complements Alliance’s buy-out last month of the remaining 50% stake in its joint venture with Irish firm M2i Holdings to take on full ownership of Erigal. The deals give Alliance a strong FDG supply network.